Search Results
Your search for all items matches 33389 pages
Showing 1 - 50AML: All-Oral Regimen Safe and Eases Treatment Administration Burden
An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine....
Overall Survival With EBRT in Hepatocellular Carcinoma
In an individual patient analysis reported in the Journal of Clinical Oncology, Moon et al found that treatment of early-stage hepatocellular carcinoma (HCC) with external-beam radiation therapy (EBRT) was associated with survival outcomes comparable to other treatment modalities such as surgical...
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
A major real-world study has found serious blood-related side effects associated with antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer therapies. Over the years, many novel ADC therapies have been approved for treating various types of cancers. The study,...
SCLC With Brain-Only Progression: Original or Substitute Systemic Therapy With or Without Brain Radiotherapy
In a Chinese retrospective cohort study reported in the Journal of Clinical Oncology, Lu et al found that adding brain radiotherapy to continued original systemic therapy produced better outcomes compared to brain radiotherapy and substitution of systemic therapy or substitution of systemic therapy ...
Five-Year Survival Analysis: Neoadjuvant Trastuzumab/Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer
In an analysis of the German phase II WSG TP-II trial reported in the Journal of Clinical Oncology, Gluz et al found that neoadjuvant trastuzumab/pertuzumab with endocrine therapy (ET) or paclitaxel were both associated with high rates of 5-year overall survival in patients with hormone receptor...
GLP-1 RAs May Be Associated With Lower Breast Cancer Incidence
Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual Meeting (Abstract 10506). The findings were also published in JCO Oncology Practice. “While our...
American Cancer Society Updates Colorectal Cancer Screening Guideline
The American Cancer Society (ACS) recently released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 years and continue through age 75 years for those with a life expectancy greater than...
Long-Term Follow-Up of Three First-Line Regimens in Mantle Cell Lymphoma
In an analysis reported in The Lancet, Dreyling et al provided long-term findings with three first-line regimens in the phase III TRIANGLE trial among patients aged 18 to 65 years with mantle cell lymphoma. Study Details In the international (13 European countries and Israel) open-label trial, 870...
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response?
A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Results were presented at the 2026 ASCO Annual Meeting (Abstract 2580). “This is really a cautionary...
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages...
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared with pembrolizumab alone in patients with high-risk resected melanoma, according to 5-year results...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO...
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Friends of Cancer Research announced the election of Richard Pazdur, MD, to its Board of Directors. Dr. Pazdur spent 26 years at the U.S. Food and Drug Administration, where he served as the founding director of the Oncology Center of Excellence and played a leading role in shaping the regulatory...
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with a family history of breast cancer will ultimately develop the disease (Abstract 10545). Although...
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer
Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recurrent endometrial cancer, according to findings presented during the Gynecologic Oncology Session at ...
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers are diagnosed, reducing the burden of stage IV cancers. However, the study did not achieve its...
Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
Results from the global phase III ASCENT-04 clinical trial found that sacituzumab govitecan combined with pembrolizumab improved progression-free survival 2 (PFS2) in patients with PD-L1–positive metastatic triple-negative breast cancer when compared to chemotherapy with pembrolizumab. PFS2 is an...
Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
According to findings from a phase III trial presented at the 2026 ASCO Annual Meeting (Abstract LBA6007), a low-cost regimen combining triple oral metronomic chemotherapy with ultra-low-dose immunotherapy significantly improved survival and reduced toxicity compared with platinum-based...
HCC: TACE Plus STRIDE With or Without Lenvatinib
Results from the phase III EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab, regular interval durvalumab) regimen, with or without the targeted therapy lenvatinib, can slow the cancer’s...
Symptom-Monitoring App Helps Patients With Advanced Cancer Maintain Quality of Life
Use of a mobile app for proactive symptom monitoring helped patients with advanced cancer who were no longer receiving active anticancer treatment maintain their quality of life and reduced hospital utilization, according to findings from a randomized controlled trial presented at the 2026 ASCO...
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) for first-line treatment can reduce tumor progression in patients with aggressive diffuse large B-cell lymphoma...
Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases
A phase III randomized trial presented at the 2026 ASCO Annual Meeting found that implanted tile-based radiation therapy significantly reduced local recurrence and improved overall survival compared with postoperative stereotactic radiotherapy (SRT) in patients undergoing surgical resection of...
Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows
Updated results from the phase III SENOMAC trial suggest that many patients with early-stage breast cancer and limited spread to sentinel lymph nodes can safely forgo axillary lymph node dissection (ALND), avoiding substantial long-term arm morbidity without compromising survival. The findings were ...
Adjuvant Selpercatinib Improves Event-Free Survival in RET-Positive Early-Stage NSCLC
Adjuvant treatment with the selective RET inhibitor selpercatinib significantly reduced the risk of disease recurrence, progression, or death among patients with resected stage IB to IIIA RET fusion–positive non–small cell lung cancer (NSCLC), according to results from the phase III LIBRETTO-432...
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in patients with advanced...
Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer
The investigational multiselective RAS(ON) inhibitor daraxonrasib may represent a new standard second-line treatment option for patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase III RASolute 302 trial. In the study, presented by Brian Wolpin, MD, MPH, of ...
PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer
Adding the androgen receptor pathway inhibitor apalutamide to androgen-deprivation therapy (ADT) before and after radical prostatectomy significantly improves outcomes for patients with localized high-risk prostate cancer, according to findings from the phase III PROTEUS trial presented during the...
Pain and Health-Related QOL With Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer
In analyses from the phase III ARANOTE trial reported in The Lancet Oncology, Morgans et al found that darolutamide was associated with prolonged times to worsening pain and worsening health-related quality of life (QOL) compared with placebo in patients with metastatic hormone-sensitive prostate...
Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer
As reported in The Lancet Oncology by Pfob et al, a pooled analysis of randomized trials showed that performance of lymph node surgery for the sole purpose of determining eligibility for CDK4/6 inhibitor treatment does not appear to be a promising strategy in patients with early breast cancer. As...
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The...
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The EGFR-targeting tyrosine kinase inhibitor sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins). Results from the phase III...
Behind the Scenes of the 2026 ASCO Annual Meeting
The ASCO Annual Meeting is one of the largest and most impactful oncology conferences of the year, featuring practice-changing data, state-of-the-art updates, developmental therapeutics, global issues, and more. The 2026 meeting is expected to showcase paradigm-shifting science, presentations from...
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). Efficacy and Safety Efficacy...
Local Radiotherapy May Help Control Oligometastatic Breast Cancer
Local radiotherapy may help control disease spread in patients with oligometastatic breast cancer, according to findings from the OLIGOMA trial presented during the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026; Abstract 5611). “Currently, patients with oligometastatic ...
BPDCN: FDA Approves Pivekimab Sunirine-pvzy
On May 27, the U.S. Food and Drug Administration (FDA) approved pivekimab sunirine-pvzy (Decnupaz), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). CADENZA Efficacy was evaluated in CADENZA (ClinicalTrials.gov...
TAILORx and RxPONDER Trials Shift to a Discovery Platform
The ECOG-ACRIN Cancer Research Group, in collaboration with the SWOG Cancer Research Network, has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-changing breast cancer clinical trials. Through the translational study EA1241, researchers will...
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
In 2016, The ASCO Post published an article titled “An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix,” highlighting the work of Robert D. Hilgers, MD—now deceased—and the Women’s Global Cancer Alliance (WGCA) in building a cervical cancer screening and prevention program in...
Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma
CB-011, the first allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy incorporating immune cloaking, achieved a high overall response rate in heavily pretreated patients with relapsed or refractory multiple myeloma in the phase I CaMMouflage trial. Dose-escalation results were...
Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions
Two larger doses of radiotherapy for prostate cancer caused no additional side effects compared to the standard five doses of radiotherapy, according to results from the HERMES trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the...
Early Breast Cancer: Is Surgery Omission Possible Following Estrogen and Ablative Radiation Therapy?
Select patients with early-stage breast cancer who achieved exceptional responses to ablative radiation therapy and endocrine therapy were able to omit surgery without disease progression, according to findings from a prospective phase II trial presented during the Congress of the European Society...
Outcomes in Patients With Breast Cancer and Obesity or T2D Receiving GLP-1 RAs
In a retrospective cohort study reported in JAMA Network Open, Tatum et al found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with reduced risk of all-cause mortality in patients with breast cancer and obesity or type 2 diabetes (T2D). Study Details The study...
Long-Term EORTC Trial Challenges Assumptions About Lymph Node Radiation Therapy in Breast Cancer
Final results from a landmark European Organisation for Research and Treatment of Cancer (EORTC) randomized trial with more than 20 years of follow-up have shown that irradiation of the internal mammary and medial supraclavicular (IM-MS) lymph nodes reduces breast cancer mortality but does not...
Addition of Olaparib to Radium-223 in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
In a phase II trial (COMRADE) reported in the Journal of Clinical Oncology, McKay et al found that the addition of olaparib to radium-223 improved radiographic progression–free survival in men with castration-resistant prostate cancer and bone metastases. Study Details In the U.S. multicenter...
Better Together: The Case for True Physician-AP Partnership in Oncology
At 8 am, the infusion chairs are already full. The oncologist is in a room seeing a new patient consult, the pharmacist is adjusting doses based on new lab values, and the advanced practitioner (AP) is sitting with a patient—reviewing symptoms, discussing how to manage treatment side effects, and ...
I Have Advanced-Stage Lung Cancer. I Refuse to Be a Victim of the Disease
I remember thinking on the day I turned 60, May 10, 2021, “This is going to be the best year of my life.” I couldn’t have been more wrong. Within weeks of feeling that swell of optimism about my future, I began experiencing a series of odd, and, seemingly unrelated symptoms leading to my eventual...
A Timely Compendium for the Era of Precision Oncology
The pace at which precision oncology has evolved over the past 2 decades, from the early promise of the Human Genome Project to the clinical reality of CAR T-cell therapy, antibody drug conjugates, and AI-assisted decision support, has made it increasingly difficult for even the most engaged...
Using Artificial Intelligence to Prescribe Cancer Drugs and Perform Other Tasks
In a recent article in The ASCO Post, we discussed increasing use of artificial intelligence (AI) in oncology and how physician-complementing AI can empower oncologists to be even better at what they do.1The reason AI is needed is that increasingly many variables need to be considered in cancer...
Survival Among Patients Treated in Community Oncology Settings Compared With National Benchmarks From SEER Database
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) when treated at community oncology practices participating in the Flatiron Health Research Network had better or comparable survival compared with national benchmark survival estimates generated by the...
Facing a Year Ahead of Unprecedented Opportunities—and Challenges
This year has marked unprecedented progress against cancer—as well as challenges. According to findings in the American Cancer Society’s Cancer Statistics, 2026 report, the 5-year relative survival rate for all cancers combined has reached a milestone of 70% for individuals diagnosed between 2015...
ASCO Expands Landmark TAPUR™ Trial
ASCO has expanded its Targeted Agent and Profiling Utilization Registry (TAPUR™) Study with two new developments: The study added its first antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (T-DXd), to determine if a wider group of patients would benefit from this medicine. Separately, the...
